Clinical Trial Update: Pazopanib Hydrochloride in Treating Patients With Metastatic Urethral Cancer or Bladder Cancer That Has Relapsed or Not Responded to Treatment [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating pazopanib hydrochloride in patients with metastatic bladder cancer, urethral cancer, or transitional cell carcinoma of the r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Transitional Cell Carcinoma of the Renal Pelvis and Ureter
• Urethral Cancer

Drugs mentioned

• Pazopanib hydrochloride (pazopanib)

Snippet

Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | Conditions: Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter | Phase 2 | Status: COMPLETED